CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published ahead of print on August 16, 2007
Clinical Journal of the American Society of Nephrology
© 2007 American Society of Nephrology
doi: 10.2215/CJN.01180307
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.01180307v1
2/5/932    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cravedi, P.
Right arrow Articles by Remuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cravedi, P.
Right arrow Articles by Remuzzi, G.

Received March 9, 2007
Accepted on June 19, 2007

ORIGINAL ARTICLES

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

Paolo Cravedi *{dagger}, Piero Ruggenenti *{dagger}1, Maria Chiara Sghirlanzoni {dagger}, and Giuseppe Remuzzi *{dagger}

*Clinical Research Centre for Rare Diseases "Aldo e Cele Daccò," Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, and {dagger}Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy


1 To whom correspondence should be addressed. E-mail: manuelap{at}marionegri.it.


  Abstract

Background and Objectives: Rituximab, given in four weekly doses, is a promising treatment for idiopathic membranous nephropathy and other immune-mediated diseases and lymphoproliferative disorders. This multidose regimen, however, may cause hypersensitivity reactions and is extremely expensive. This study was aimed at evaluating whether titrating rituximab to circulating CD20 B cells may improve safety and limit costs of treatment.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Society of Nephrology.